Gencor’s fenugreek extract granted patent for supporting sexual function and hormones
Gencor Pacific has received a U.S. patent (US 10,576,118 B2) for its fenugreek extract, Testofen, which is standardized to a 50% minimum content of Fenuside.
Photo © iStockphoto.com/monkeybusinessimages
Gencor Pacific (Irvine, CA) has received a U.S. patent (US 10,576,118 B2) for its fenugreek extract, Testofen, which is standardized to a 50% minimum content of Fenuside. The patent was granted for the improvement of sexual function, reducing further decline of sexual hormones, and improvement in sexual hormonal levels in healthy aging males.
“We have made a significant investment into the clinical validation of Testofen, and receiving this patent further progresses our commitment and intellectual property supporting this superior fenugreek extract,” said Chase Shryoc, vice president of sales of Gencor, in a press release. “Testofen is the perfect addition for product formulations designed to support healthy sexual function, and performance.”
A number of double-blind placebo-controlled clinical trials have demonstrated the efficacy and safety of Testofen. The most recently published trial found that supplementation with Testofen significantly reduced body fat, increased muscle mass, and increased testosterone levels.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
